Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com

Chemistry and Pharma Blogs:
Pharmalot
Org Prep Daily
On Pharma
One in Ten Thousand
Away From the Bench
QDIS Blog
Chemical Musings
In Vivo Blog
The Chemblog
Molecule of the Day
Kinase Pro
Drugs and Poisons
Jungfreudlich
Chembark
Social Detritus
Pharmagossip
Whistling in the Wind
Organometallic Current
Great Molecular Crapshoot
Post Doc Ergo Propter Doc
A Chemist's Lab Notebook
The Curious Wavefunction Totally Synthetic
Pharma's Cutting Edge
The F- Blog
Synthetic Environment
Atom Pusher
Chemistry World Blog
Carbon-Based Curiosities
Eye on FDA
Hdreioplus
Closeted Chemistry
Chemical Forums
Curly Arrow
Power of Goo
Carbon Tet
Totally Medicinal
Sceptical Chymist
Lamentations on Chemistry
PeterMR
Mining Drugs
Regulatory Affairs of the Heart
Making Graphite Work
Liquid Carbon
Half-Decent Pharma Blog


Science Blogs and News:
The Loom
Uncertain Principles
The Crimson Canary
Fierce Biotech
Blogs for Industry
The Futile Cycle
Omics! Omics!
Young Female Scientist
Notional Slurry
Life of a Lab Rat
TP With Page Numbers
Nobel Intent
SciTech Daily
Is This Thing On?
Science Blog
Eastern Blot
Oncology Updates
FuturePundit
Flags and Lollipops
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Daily Biomed
Voyage to Arcturus
Adventures in Ethics and Science
Terra Sigillata
Transterrestrial Musings
The Mass Spectrometry Blog
Nodal Point
Slashdot Science
A Scientist's Life
Living the Scientific Life
John Johnson
Humans in Science
Tobias Sing's Bioinformatics Blog
Speculist
Science, Shrimp and Grits
Biopeer
Cosmic Variance
The Capsule
Zeroth Order Approximation
Science Library Blog
Biology News Net


Medical Blogs
MedPundit
Med Tech Sentinel
DB's Medical Rants
Dr. Charles
RangelMD
GruntDoc
The Health Care Blog
Cut to Cure
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Asymmetrical Information
Belmont Club
Man Without Qualities
Belgravia Dispatch
Mickey Kaus
Colby Cosh
Progressive Reaction
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
Check out Jevon MacDonald on the "uncertain future of blogging"

In the Pipeline

« You'd Think It Was An Election Year or Something | Main | Primum Non Nocere, Eh? »

June 21, 2004

Le Dernier Cri

Email This Entry

Posted by Derek

Mentioning all the nanostructure papers in the journals brings up the topic of fashions in chemistry. We've got 'em, all right. Waves like this tend to wash over the literature every few years. (I can only speak for organic chemistry, but I assume that it's the same in the other disciplines.)

For example, only in the last couple of years have we begun to escape from the olefin metathesis craze. That's a useful reaction, and I can't make fun of it on its face. But a few years ago, it seemed that everyone with two alkenes in their lab was finding a way to get them in the same flask with some Grubbs catalyst or whatnot. People looked at the reaction and said "Hey, that's neat. I could do that", and they did.

Of course, people also look at these things and think "Hey, that's neat. I could publish that" or "Hey, that's neat. I could get funded for that", and those reasons carry a lot of weight. So journal editors and the reviewers at granting agencies carry some responsibility for these fads, but they're just as human as the rest of us. Most of the time.

These bursts of activity can serve a useful purpose. The state of the art advances rapidly when everyone's trying to improve it, as you'd figure. The best examples of waves of interest have a can-you-top-this quality in them; the worst have a bunch of chemists just doing the same thing because everyone else is doing it.

There are even fashionable molecules, ones that have been synthesized over and over again, because they come in handy to show that your new synthetic method is good for something. (That's not a line of argument that I find very compelling, but it's a common one.) An insect attractant called brevicomin is a good example. I'm sure that I've seen six or eight synthetic routes to that, and it's not like I've been collecting them, either. Twenty years or so ago, the jokes were about a molecule called cis-jasmone, which turned up over and over again when someone wanted to prove their synthetic moves.

But since we're talking about fashion, I should note that the whole field of natural product total synthesis isn't as fashionable as it used to be. That's a larger topic worth a post of its own, but it's something that's had its practioners a bit worried and defensive the last few years.

Comments (2) + TrackBacks (0) | Category: The Scientific Literature


COMMENTS

1. The Un-Candidate on June 21, 2004 10:37 AM writes...


What are you talking about!?! It's as relevant as ever! We can solve all sorts of problems through total synthesis!

Oh, wait...

Permalink to Comment

2. Derek Lowe on June 21, 2004 3:57 PM writes...

As it turns out, I was way too conservative in my estimate in paragraph 5. A quick look through the literature shows at least twenty syntheses of endo- or exo-brevicomin.

I remember hearing a professor in the field express scorn in 1985 at yet another synthesis that had appeared, but clearly a dozen more have shown up since then. It seems that if you have a route to chiral hydroxyaldehydes, you are required by law to synthesize brevicomin.

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Pfizer's Prospects: Just Ducky
Happy Fourth of July
I Can Has Ugly Molecules?
More Pfizer Layoffs?
Leaving Comments: A Fix
The Gates Foundation: Dissatisfied With Results?
Another Alzheimer's Compound Goes Down
Unknown - But You Can Buy It